These data suggest that in melanoma cells resistant to PLX-4720, autocrine Gal-1 signaling is critical to support viability in the presence of the drug, featuring a previously unknown mechanism of refractoriness to BRAF-targeted drugs in melanoma. This evidence concerns the gene LGALS1 and melanoma.